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Abstract
Background: This study was undertaken to prospectively evaluate the impact of partial portal decom-
pression on renal haemodynamics and renal function in patients with cirrhosis and portal hypertension.
Methods: Fifteen consecutive patients (median age 49 years) with cirrhosis underwent partial portal
decompression through portacaval shunting or transjugular intrahepatic portosystemic shunting (TIPS).
Cirrhosis was caused by alcohol in 47%, hepatitis C in 13%, both in 33% and autoimmune factors in 7%
of patients. Child class was A in 13%, B in 20% and C in 67% of patients. The median score on the Model
for End-stage Liver Disease (MELD) was 14.0 (mean 15.0  7.7). Serum creatinine (SrCr) and creatinine
clearance (CrCl) were determined pre-shunt, 5 days after shunting and 1 year after shunting. Colour-flow
Doppler ultrasound of the renal arteries was also undertaken with calculation of the resistive index (RI) and
pulsatility index (PI). Changes in the portal vein–inferior vena cava pressure gradient with shunting were
determined.
Results: With shunting, the portal vein–inferior vena cava gradients dropped significantly, with signifi-
cant increases in PI in the early period after shunting. Creatinine clearance improved in the early
post-shunt period. However, SrCr levels did not significantly improve. At 1 year after shunting, both CrCl
and SrCr levels tended towards pre-shunt levels and the increase in PI did not persist.
Discussion: Partial portal decompression improves mild to moderate renal dysfunction in patients with
cirrhosis. Early improvements in renal function after shunting begin to disappear by 1 year after shunting.
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Introduction
Renal dysfunction frequently occurs in patients with cirrhosis and
portal hypertension, with symptoms ranging from an inability to
concentrate urine to oliguria and renal failure. Despite its fre-
quency, the aetiology of renal dysfunction in patients with cirrho-
sis and portal hypertension is not fully understood. Recent
evidence suggests that increased renovascular arterial tone may be
an important determinant of renal dysfunction in patients with
cirrhosis.1 Despite notable splanchnic arterial vasodilatation and
hyperdynamic circulation, patients with cirrhosis show increased
renal arterial tone, resulting in poor renal perfusion. Specifically,
the increased renal arterial tone leads to the activation of the
renin–angiotensin system and increased levels of angiotensin II
and aldosterone, which, in turn, favour renal artery vasoconstric-
tion and further promote renal ischaemia and fluid retention.2
Early diagnosis of mild to moderate renal impairment in
patients with cirrhosis can be difficult. Conventional renal func-
tion tests, such as serum creatinine (SrCr) and blood urea nitro-
gen (BUN), are not sensitive indicators of early renal impairment,
with elevation of SrCr occurring only after a considerable portion
of renal parenchyma is functionally impaired. In addition, deter-
mination of urine electrolytes in patients with cirrhosis is gener-
ally not reliable because most of these patients are treated with
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diuretics for fluid retention and ascites. A more sensitive test to
determine renal function is 24-hour creatinine clearance (CrCl),
although its determination is cumbersome and often not possible
in an acute-care setting.
The application of non-invasive diagnostic technologies, such
as colour-flow Doppler ultrasound, in the study of renal haemo-
dynamics can document tone in the renal artery circulation. Spe-
cifically, arterial tone can be determined with calculation of the
resistive index (RI) and pulsatility index (PI).3 In patients with
cirrhosis, these parameters tend to be elevated relative to those in
healthy individuals or in other patients with ascites unrelated to
cirrhosis and portal hypertension,4 reflecting increased tone in the
renal vascular circulation.
In this study, we measured changes in renal function and renal
haemodynamics occurring in patients immediately after and 1
year after partial portal decompression through transjugular
intrahepatic portosystemic shunt (TIPS) or small-diameter pros-
thetic H-graft portacaval shunt (HGPCS) because of bleeding
varices and portal hypertension. The purpose of this study was to
determine if and how partial portal decompression influences
renal function and haemodynamics. Our hypothesis in under-
taking this study was that partial portal decompression would
improve renal function by increasing renal perfusion, as deter-
mined by calculation of the RI and PI.
Materials and methods
With Institutional Review Board approval, a randomized trial
comparing TIPS with small-diameter prosthetic HGPCS began in
1993.5,6 Patients with bleeding oesophagogastric or intestinal
varices or bleeding from portal gastropathy secondary to cirrhosis
and portal hypertension were enrolled. All patients had failed
or were not amenable to endoscopic sclerotherapy or banding.
Patients were randomized in pairs to TIPS or small-diameter
prosthetic HGPCS through computer-generated random
numbers. Shunting was always undertaken as a definitive therapy
and never as a bridge to transplantation.
Prior to shunting, all patients underwent routine measure-
ments of serum electrolytes, creatinine, BUN, albumin, SGPT
(serum glutamic pyruvic transaminase) and SGOT (serum
glutamic oxaloacetic transaminase), bilirubin, prothrombin time
(PT), international normalized ratio (INR) and partial thrombo-
plastin time (PTT). Ascites was defined as absent, controlled
(required salt and volume restriction, as well as diuretics) or
refractory (present despite full medical therapy). Encephalopathy
was defined as absent, mild (encephalopathy effectively avoided/
treated by lactulose and a protein-restricted diet) or severe
(patient requiring hospitalization for encephalopathy despite full
medical therapy). Each patient was assigned a Child class.AModel
for End-stage Liver Disease (MELD) score7 was also calculated for
each patient pre-TIPS or portacaval shunt.
The techniques for the construction of the small-diameter pros-
thetic shunt and TIPS have been described previously.5 Briefly, the
small-diameter prosthetic portacaval shunt was constructed using
an 8-mm, ring-reinforced polyfluorotetraethylene (PFTE) graft,
measuring 3 cm from toe to toe, with bevels at 90 degrees to one
another. TIPS was undertaken through cannulation of the right
internal jugular vein.AWallstent 8–10 mm indiameter bridged the
right hepatic vein to the right branch of the portal vein. The stent
was dilated to achieve adequate portal decompression. With each
shunt, pre- and post-shunt portal vein pressures and portal vein–
inferior vena cava pressure gradients were determined. Five days
after shunting, shunt patency and function were assessed utilizing
trans-shunt venography to measure trans-shunt pressures. Five
days after shunting, all patients were haemodynamically stable,
regardless of the shunt undertaken.
Fifteen consecutive patients, a subgroup of a large, randomized
trial,5,6 underwent pre-shunt, post-shunt and late (1 year after
shunting) assessment of renal function, including measurement
of 24-hour urinary CrCl. Similarly, the RI and PI of the main renal
arteries and of two intraparenchymal branches of the renal arter-
ies were calculated before, 5 days after and 1 year after shunting
using colour-flowDoppler ultrasound.Waveforms were measured
at three different sites for each renal artery and at two different
intraparenchymal branches of each renal artery. Colour-flow
Doppler ultrasound was undertaken utilizing a 128 XP scanner
with a 3.5 MHz and 2.5 MHz transducer (Acuson Corp., Moun-
tain View, CA, USA).
The RI was calculated with electronic callipers, using the fol-
lowing formula:
Peak systolic frequency shift   End diastolic frequency ( )- shift
Peak systolic frequency shift
( )
( )
The PI was similarly calculated, using the formula:
Peak systolic velocity   End diastolic velocity
Mean ve
( ) ( )-
locity( )
Data were compiled into a Microsoft excel spreadsheet and are
presented as mean standard deviation (SD). Comparisons of
renal function and renal haemodynamics before and after partial
portal decompression were made utilizing anova matched-
samples test. Comparison between patients undergoing TIPS vs.
H-graft shunts were made using one-way anova or Mann–
Whitney U-test. Statistical significance was accepted with 95%
confidence.
Results
Beginning in 1993, 132 patients were enrolled in a prospective
randomized trial comparing TIPS with small-diameter prosthetic
HGPCS.5,6 Among these, 15 consecutive patients (six undergoing
TIPS and nine undergoing H-graft shunts) underwent measure-
ments of renal function and renal haemodynamics before and
after shunting and at 1 year after shunting (Table 1). Their median
age was 49 years. Cirrhosis was caused exclusively by alcohol in
230 HPB
HPB 2009, 11, 229–234 © 2009 International Hepato-Pancreato-Biliary Association
seven (47%) patients and Child classification was C in 10 (67%)
patients. The median MELD score was 14.0 (mean 15.0 7.7).
Shunting was undertaken with urgency in 20% of patients as they
experienced significant variceal recurrent bleeding after their
operative evaluation. Preoperative ascites was determined to be
mild in six (40%) patients (Table 1).
MELD score, Child class, Child–Pugh score, cause of cirrhosis,
age and gender were similar in both the TIPS and HGPCS groups.
Both HGPCS and TIPS always produced decreased portal pres-
sures and portal vein–inferior vena cava pressure gradients
(Table 2). There were no significant differences in pre- or post-
shunt portal vein pressures or in portal vein–inferior vena cava
pressure gradients between patients undergoing HGPCS or TIPS.
All shunts were patent with late follow-up by colour-flow Doppler
ultrasound and transvenous study.
Mean pre-shunt SrCR was 1.2 0.769 mg/dl and was not sig-
nificantly greater than the mean early post-shunt (day 5) SrCr of
0.95 0.585 mg/dl. Mean pre-shunt CrCl was 74 38.3 ml/min
and was significantly lower than the mean early post-shunt (post-
operative day 5) CrCl of 117 67.07 ml/min (P < 0.05). One year
after shunting, mean SrCr (0.93 0.333 mg/dl) was not signifi-
cantly lower than it had been prior to shunting. Similarly, at 1 year
after shunting, mean CrCl (97 48.6 ml/min) was not signifi-
cantly greater than it had been prior to shunting (Table 3). There
were no differences between post-shunt and late (at 1 year) levels
of SrCr and CrCl.
There were no meaningful differences in mean pre-shunt
(P = 0.56), mean post-shunt (P = 0.7) or mean 1 year post-shunt
(P = 0.6) SrCr values between the small-diameter HGPCS and
TIPS groups. Similarly, there were no differences in mean pre-
shunt (P = 0.7), post-shunt (P = 0.9) and 1 year post-shunt
(P = 0.4) CrCl values between the groups (Table 4).
Mean pre-shunt renal artery RI was 0.73 0.08. Mean early
post-shunt (postoperative day 5) renal artery RI was 0.76 0.07
(non-significant difference). Mean renal artery RI at 1 year was
0.72 0.067, which was not significantly lower than the pre-
shunt value (Table 3). Mean pre-shunt renal artery PI was
1.40 0.412. Mean post-shunt renal artery (postoperative day 5)
PI was higher, at 1.68 0.437 (P < 0.05). Mean renal artery PI at
1 year was 1.44 0.299, which was not significantly higher than
the pre-shunt value (Table 3). There were no significant differ-
ences in mean pre-shunt RI or PI, mean early post-shunt RI or PI,
and mean 1-year post-shunt RI or PI between the HGPCS and
TIPS groups (Table 4).
Discussion
Renal dysfunction has long been believed to complicate the man-
agement of patients with cirrhosis and portal hypertension. Only
recently, with the development of MELD, has the importance of
renal function on the overall survival of patients with cirrhosis
been formally recognized.7 In predicting outcomes of patients
with cirrhosis, MELD has been shown to be superior to the
Table 1 Clinical data for 15 patients undergoing partial portal
decompression
Median age, years 49
Gender
Male 80%
Aetiology of cirrhosis
EtOH 47%
Hepatitis C 13%
EtOH + hepatitis C 33%
Autoimmune causes 7%
Child class
A 13%
B 20%
C 67%
MELD score
Median 14
Mean  SD 15  7.7
Type of varices
Oesophageal varices 33%
Gastric varices 27%
Oesophageal + gastric varices 33%
Intestinal varices 7%
Pre-shunt therapy
Sclerotherapy 65%
Banding 55%
Circumstances of shunting
Elective 80%
Urgent 20%
Pre-shunt ascites
Controlled 40%
Refractory 20%
Pre-shunt encephalopathy (mild) 20%
EtOH, ethyl alcohol; MELD, Model for End-stage Liver Disease; SD,
standard deviation
Table 2 Portal vein (PV) and inferior vena cava (IVC) haemodynamics
before and after transjugular intrahepatic portosystemic shunt, and
before and after 8-mm H-graft portacaval shunt
Pre-shunt Post-shunt
Transjugular intrahepatic portosystemic shunt
Portal vein pressure, mmHg (n = 6) 30  6.5 24  8.3
Inferior vena cava pressure, mmHg (n = 6) 16  2.1 17  7.9
PV–IVC pressure gradient, mmHg (n = 6) 14  4.3 8  1.8a
H-graft portacaval shunt
Portal vein pressure, mmHg (n = 9) 29  8.5 29  8.8
Inferior vena cava pressure, mmHg (n = 9) 13  7.4 20  6.7
PV–IVC pressure gradient, mmHg (n = 9) 16  5.3 9  3.5a
aLess than pre-shunt, Wilcoxon matched-pairs test: P < 0.05
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traditional Child–Pugh classification and other systems of risk
stratification.8–10 Although the number of patients in this study is
small, trends in renal function and perfusion are apparent. Early
improvements after shunting in renal function (especially CrCl)
and perfusion (especially PI) are generally lost by 1 year after
shunting as renal function and perfusion return towards pre-
shunt levels. Although renal function is now known to impact
survival after portasystemic shunting, this study failed to docu-
ment a significant beneficial impact of partial portal decompres-
sion on renal function and renal haemodynamics in patients with
cirrhosis and bleeding varices.
Our patients were mostly older men with advanced alcoholic
cirrhosis, who were undergoing portal decompression to treat
variceal haemorrhage refractory to or not amenable to sclero-
therapy or banding. Prior to shunting, the patients were not in
imminent need of or were not eligible for (e.g. because of alco-
holism) transplantation.More than 15 patients were enrolled into
the study protocol to study liver function after shunting; some
died prior to the 1-year follow-up and are excluded from the data
analysis. Patients undergoing TIPS or H-graft portasystemic
shunting were similar. Ascites, when present, was generally mild
and well-controlled with oral diuretics. A minority, although a
notable number, had mild encephalopathy before shunting. The
patients underwent postoperative study on postoperative day 5 to
accommodate haemodynamic changes preceding shunting (e.g.
variceal bleeding) and to standardize the day of study after shunt-
ing to eliminate untold variables that might complicate renal
function or haemodynamics. The patients were all haemodynami-
cally stable at this point. Although none of our patients presented
with hepatorenal syndrome, mean SrCr was greater than normal,
although not by much, and mean CrCl was nearly half of normal
values. In addition, as reported by others,6 our patients demon-
strated increased pre-shunt renal arterial tone with elevated RI
and PI values. Increased serum levels of aldosterone and angio-
tensin II, typical in patients with cirrhosis, could and should be
responsible for increased renal arterial tone.3 Ultimately, the
resulting renal hypoperfusion should be primarily responsible for
the impaired renal function seen.
Optimal treatment of severe renal dysfunction in patients with
cirrhosis is controversial. Hepatorenal syndrome, acute renal dys-
function in the setting of advanced cirrhosis, has traditionally
been treated with medical therapy, including intravenous hydra-
tion, generous diuresis, blood products and albumin. In addition,
the administration of vasoconstrictors like vasopressin has been
associated with a significant improvement in renal function in
patients with hepatorenal syndrome.11–14 The improvement in
renal perfusion with therapy in hepatorenal syndrome is related to
an increase in systemic vascular resistances, a reduction of portal
pressure, and the suppression of endogenous vasoconstrictor
activity. Furthermore, oral misoprostol, an analogue of prostag-
landin E (PGE)-1, has been reported to improve renal dysfunction
in patients with cirrhosis, but its application is limited by toxic-
ity.15 Unfortunately, these medications provide temporary rather
than durable improvement of extreme renal dysfunction and,
generally, are not effective in hepatorenal syndrome. Additionally,
prospective studies are lacking.16
Surgical, rather than medical, management has proven to be
more efficacious in the treatment of renal dysfunction in patients
Table 3 Early and late changes in renal function and renal haemodynamics after partial portal decompression
Serum creatinine, mg/dl Creatinine clearance,
ml/min
Resistive index Pulsatility index
Pre-shunt 1.2  0.769 74  38.3 0.73  0.080 1.4  0.412
Post-shunt 0.95  0.585 117  67.07a 0.76  0.077 1.68  0.437a
1 year 0.93  0.333 97  48.6 0.72  0.067 1.44  0.299
aDifference to pre-shunt, P < 0.05 (ANOVA matched-samples test)
Table 4 Pre-shunt and early and late changes in renal function and renal haemodynamics after H-graft portacaval shunt or transjugular
intrahepatic portosystemic shunt
Serum creatinine, mg/dl Creatinine clearance, ml/min Resistive index Pulsatility index MELD
TIPS (n = 6)
Pre-shunt 1.4  1.2 80  54 0.7  0.1 1.4  0.6 16  11
Post-shunt 1.1  0.9 120  79 0.8  0.1 1.8  0.6 –
1 year 1.0  0.4 84  14 0.7  0.1 1.5  0.4 –
HGPCS (n = 9)
Pre-shunt 1.0  0.4 70  27 0.7  0.1 1.4  0.3 14  5
Post-shunt 0.9  0.3 116  63 0.8  0.1 1.7  0.3 –
1 year 0.9  0.3 105  62 0.7  0.04 1.4  0.3 –
MELD, Model for End-stage Liver Disease; TIPS, transjugular intrahepatic portosystemic shunt; HGPCS, H-graft portacaval shunt
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with cirrhosis. Although liver transplantation represents the
definitive treatment for patients with cirrhosis and hepatic
induced renal dysfunction, procedural risk, cost, shortage of liver
donors, and the potentially high rate of perioperative morbidity in
patients suffering pre-transplant renal insufficiency limit the
applicability of such therapy.17 Furthermore, patients with cirrho-
sis and renal dysfunction may otherwise have adequate hepatic
reserve and, therefore, not qualify for liver transplantation.
In the early 1970s, isolated reports documented the beneficial
effect of portal decompression attained through large-bore, side-
to-side portacaval shunts in patients with hepatorenal syndrome.
However, these shunts did not become accepted treatment for
hepatorenal syndrome because of excessive associated mortality
and morbidity.18 The introduction of TIPS has led to the recon-
sideration of portal decompression to improve renal dysfunction
in patients with cirrhosis, particularly in those with hepatorenal
syndrome. In the past decade, several reports have documented
the relative efficacy of partial portal decompression achieved
through TIPS in improving renal function in patients with
cirrhosis.19–25 More recently, TIPS has been shown to improve
renal perfusion and glomerular perfusion rate and to decrease the
activity of vasoactive substances, thereby improving renal func-
tion.26 This report adds credibility to those findings by adding to
our understanding of the underlying physiology. We believe that
the observations contained herein are primarily a result of partial
portal decompression and not issues of postoperative manage-
ment, which is another good reason for studying patients on post-
operative day 5 rather than sooner.
In this study, the probability of finding significant changes in
renal function and haemodynamics with partial portal decom-
pression was limited by the small number of patients studied.
Nonetheless, we found that partial portal decompression, as
attained through TIPS or small-diameter prosthetic HGPCS, sig-
nificantly improved mild to moderate renal dysfunction in
patients with cirrhosis. In the early postoperative period, although
soon after shunting, mean SrCr was not significantly better than
before shunting. CrCl was significantly better than before shunt-
ing. However, at 1 year after shunting, CrCl was not significantly
better than before shunting as it was found to return towards
pre-shunt levels. Interestingly, soon after shunting there was a
significant increase in renal arterial tone, with PI values higher
than before shunting. Increased renal arterial tone is likely to be
related to autoregulation of the renal circulation, which is
impacted after shunting by increased cardiac output.27 At 1 year
after shunting, renal arterial tone returned to pre-shunt levels,
probably as cardiac output decreased towards pre-shunt levels.
Changes in renal function and renal haemodynamics did not
differ significantly between patients undergoing TIPS and those
undergoing small-diameter HGPCS, presumably because of simi-
larities in the mechanism (i.e. central shunts) and degree of portal
decompression. Observations about renal function noted herein
reflect the results of perioperative management, variceal blood
loss, volume resuscitation and patient care less than the results of
partial portal decompression. The partial portal decompression
attained through these shunts is a portal vein–inferior vena cava
venous fistula and results in increased blood return to the heart
with generally increased central venous pressures. The changes in
renal function seem to represent a result of portal decompression,
given the duration of effect and the fact that patients undergoing
either shunt are well by post-shunt day 5, when they are generally
ready for discharge. The inclusion of more patients may have led
to a statistical difference between renal function at 1 year vs. that
before shunting. The inclusion of patients with worse liver func-
tion would have relatively minimized the impact of partial portal
decompression.
In conclusion, this small, prospective study documents that, in
the early period after shunting, partial portal decompression
improves mild to moderate renal dysfunction in patients with
cirrhosis and bleeding varices with increased venovascular tone.
Improvements seen early after shunting are generally lost by 1 year
after shunting and, presumably, given enough time, renal dysfunc-
tion would completely return to pre-shunt levels.
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